Core Viewpoint - Xianjian Technology (01302) saw a stock increase of over 4%, closing at HKD 1.79 with a trading volume of HKD 37.76 million, following the approval of its innovative medical device by the National Medical Products Administration [1] Group 1: Product Approval - The Concave Supra integrated arch three-branch reconstruction system, co-developed by Professor Shu Chang from the National Center for Cardiovascular Diseases and Xianjian Technology, has been approved for entry into the special review procedure for innovative medical devices, known as the "green channel" for national innovation [1] - This marks the 17th product from Xianjian Technology to be approved for the national innovation "green channel" as an independently developed innovative product [1] Group 2: Product Features - The CS stent system is designed for minimally invasive treatment of complex aortic arch aneurysms and penetrating ulcers, representing the world's first integrated three-branch reconstruction solution without brain ischemia [1] - The product will complement Xianjian's unique overall solution for endovascular treatment of aortic arch lesions, which includes innovative product matrices for chimney technology and in-situ fenestration technology, as well as the SureCham single-branch stent system [1]

Group 1 - Northeast Securities expects a net profit of 1.477 billion yuan in 2025, a year-on-year increase of 69.06% [1] - Gansu Energy anticipates a net profit of 1.95 billion to 2.1 billion yuan in 2025, representing a year-on-year growth of 18.6% to 27.72% [2] - Ningbo Bank reports a projected net profit of 29.333 billion yuan in 2025, with an 8.13% year-on-year increase [3] Group 2 - Qianyuan Power forecasts a net profit of 567 million to 633 million yuan in 2025, indicating a year-on-year growth of 160% to 190% [5] - Batian Co. expects a net profit of 890 million to 980 million yuan in 2025, reflecting a year-on-year increase of 117.53% to 139.53% [6] - Tongfu Microelectronics anticipates a net profit of 1.1 billion to 1.35 billion yuan in 2025, with a year-on-year growth of 62.34% to 99.24% [7] Group 3 - Zhongyuan Nepe expects a net profit of 368 million to 428 million yuan in 2025, representing a year-on-year increase of 80.47% to 109.9% [8] - Huajin Co. predicts a net loss of 1.6 billion to 1.9 billion yuan in 2025, compared to a loss of 2.795 billion yuan in the previous year [9] - Xinghua Co. anticipates a net loss of 420 million to 560 million yuan in 2025, up from a loss of 380 million yuan in the previous year [4] Group 4 - Huayuan Holdings expects a net profit of 107 million to 118 million yuan in 2025, a year-on-year increase of 50.98% to 66.82% [12] - Taishan Petroleum forecasts a net profit of 130 million to 165 million yuan in 2025, indicating a year-on-year growth of 30.88% to 66.11% [13] - Jiuqi Software anticipates a net profit of 40 million to 60 million yuan in 2025, recovering from a loss of 156 million yuan in the previous year [21] Group 5 - Jin Fang Energy expects a net profit of 109 million to 143 million yuan in 2025, reflecting a year-on-year increase of 123.97% to 193.7% [16] - He Sheng New Materials anticipates a net profit of 152 million to 171 million yuan in 2025, representing a year-on-year growth of 55% to 75% [24] - Yuedong Microelectronics predicts a net loss of 340 million to 425 million yuan in 2025 [14] Group 6 - Aibo Medical plans to acquire at least 51% of Demai Medical, with an estimated valuation of the target company not exceeding 1 billion yuan [26] - Zhaoshang Shipping intends to build four 3000TEU container ships with a total investment of no more than 1.324 billion yuan [18] - Zhongtung High-tech's subsidiary has confirmed an increase in mineral resources, adding significant quantities of tungsten and other metals [27]

（记者 曾健辉） 每经头条（nbdtoutiao）——"一周干完一年的活"，一款AI编程工具让硅谷程序员集体"上瘾"！科技公 司CEO：一辈子钻研的技能被它一次性解决，让人兴奋又恐惧 每经AI快讯，创新医疗1月20日晚间发布公告称，创新医疗管理股份有限公司阮光寅董事持有公司股份 约154万股，占公司总股本的0.3492%，计划在本公告披露之日起15个交易日后的三个月内，以集中竞 价交易方式减持公司股份，合计减持数量不超过约39万股，即不超过公司总股本的0.0873%。 ...

人民财讯1月20日电，创新医疗（002173）1月20日公告，持股0.3492%的董事阮光寅拟减持公司不超 38.52万股，即不超公司总股本的0.0873% ...

格隆汇1月20日丨创新医疗(002173.SZ)公布，阮光寅董事持有公司股份1,540,987股，占公司总股本的 0.3492%，计划在本公告披露之日起15个交易日后的三个月内，以集中竞价交易方式减持本公司股份， 合计减持数量不超过385,200股，即不超过公司总股本的0.0873%。 ...

证券代码：002173 证券简称：创新医疗 公告编号：2026-003 创新医疗管理股份有限公司 关于董事减持股份的预披露公告 阮光寅董事保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 创新医疗管理股份有限公司（以下简称"公司"）阮光寅董事持有公司股份 1,540,987 股，占公司总股本的 0.3492%，计划在本公告披露之日起 15 个交易日 后的三个月内，以集中竞价交易方式减持本公司股份，合计减持数量不超过 385,200 股，即不超过公司总股本的 0.0873%。 公司于近日收到阮光寅董事提交的《股份减持计划告知函》。根据《上市公 司股东减持股份管理暂行办法》、《上市公司董事、监事和高级管理人员所持本公 司股份及其变动管理规则》、《深圳证券交易所上市公司自律监管指引第 18 号— —股东及董事、监事、高级管理人员减持股份》等有关规定，现将具体内容公告 如下： 一、股东的基本情况 1、股东名称：阮光寅 2、股东持有股份的数量、占公司总股本的比例：截至本公告披露日，阮光 寅持有公司股份 1, ...

创新医疗公告，阮光寅董事持有公司股份154.1万股，占公司总股本0.3492%，拟自公告披露后15个交易 日后的三个月内，以集中竞价方式减持不超过38.52万股，占公司总股本0.0873%。股份来源为公司首次 公开发行前已发行的股份（含因资本公积金转增股本相应增加的股份）。如公司发生送股、资本公积金 转增股本、配股等除权除息事项，减持数量将相应调整，减持价格按市场价格确定。 ...

Group 1 - The core viewpoint of the news is that Innovation Medical's stock has experienced significant fluctuations, with a year-to-date increase of 33.66% but a recent decline of 18.11% over the past five trading days [1] - As of January 20, the stock price was 28.75 yuan per share, with a total market capitalization of 12.687 billion yuan [1] - The company has seen a net outflow of 14.05 million yuan in principal funds, with large orders showing a buy of 57.736 million yuan and a sell of 72.818 million yuan [1] Group 2 - Innovation Medical operates primarily in the medical services sector, with 99.73% of its revenue coming from medical services and only 0.27% from other sources [1] - As of September 30, the number of shareholders increased by 58.75% to 130,200, while the average circulating shares per person decreased by 37.01% to 3,196 shares [2] - For the period from January to September 2025, the company reported a revenue of 597 million yuan, a year-on-year decrease of 2.11%, while the net profit attributable to shareholders increased by 116.97% to 4.7244 million yuan [2]

证券之星消息，截至2026年1月16日收盘，创新医疗(002173)报收于29.2元，下跌8.18%，换手率 24.68%，成交量102.74万手，成交额31.13亿元。 1月16日的资金流向数据方面，主力资金净流出2.52亿元，占总成交额8.11%，游资资金净流出1.7亿 元，占总成交额5.45%，散户资金净流入4.22亿元，占总成交额13.56%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 创新医疗2025年三季报显示，前三季度公司主营收入5.97亿元，同比下降2.11%；归母净利润472.44万 元，同比上升116.97%；扣非净利润-2946.98万元，同比上升6.05%；其中2025年第三季度，公司单季度 主营收入1.96亿元，同比下降3.16%；单季度归母净利润1608.57万元，同比上升236.15%；单季度扣非 净利润-1658.58万元，同比下降12.36%；负债率17.84%，投资收益2950.55万元，财务费用60.55万元， 毛利率10.08%。创新医疗（002173）主营业务：提供医疗服务。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单 ...

Group 1 - The core point of the article highlights that Innovation Medical (002173) experienced a significant decline in stock price, closing at 29.2 yuan on January 16, down 8.18% [1][2] - The stock has seen a continuous drop for four consecutive days, with two of the last five trading days recording a decline of over 5% [2] - In the first ten trading days, the stock price had an overall increase of 35.44%, despite the recent downturn [2] Group 2 - On January 16, the stock recorded a trading volume of 1.03 billion yuan, with a turnover rate of 24.68% and a total transaction volume of 1.0274 million hands [1] - During the same day, the main funds experienced a net outflow of 2.52 billion yuan, while retail investors saw a net inflow of 4.22 billion yuan [1] - Over the first ten trading days, the main funds had a cumulative net outflow of 9.42 billion yuan, while the financing balance increased by 3.25 billion yuan [1]